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Tumor necrosis factor alpha (TNF) is a multifunctional cyto-
kine, which possesses various biologic functions depending on
the type of the cells and the physiological context. TNF is synthe-
sized by immune cells as well as malignant cells. Accordingly,
TNF plays an important role in the tumor and microenvironment
communication as well as systemic response to the disease. TNF
gene is located at HLA class III gene locus (6p21.3) and contains
several sites of single nucleotide polymorphisms in promoter,
which modify TNF gene expression. G to A substitution at posi-
tion 238 (rs361525) decreases TNF gene expression whereas
the G to A substitution at position 308 (rs1800629) increases
the expression. Studies on the possible association of these poly-
morphisms with various malignancies risk yielded contradictory
results depending on ethnicity. Breast cancer (BC) is a multifacto-
rial disease with clinicomorphological heterogeneity. Pathways of
the main BC associated molecules (ER, PR, Her2) have crossroads
with TNF signaling. The goal of the study was to identify possible
TNF polymorphism effects on BC predisposition and prognosis in
Russian patients.
Materials and methods: DNA from 413 women with newly
diagnosed BC and 226 women without oncological, autoimmune
or inflammatory diseases (control group) was examined. Allelic
variants of 238(G/A) TNF were determined by a RFLP-PCR, the
308(G/A) TNF polymorphism was analyzed by allele-specific
PCR. Additionally Ile655Val HER2 polymorphism was tested by
RFLP-PCR in142 BC patients. The comparison of genotypes
frequencies was performed using the Fisher’s exact test. Overall
survival (OS) rate of BC patients was the criterion for estimation
of polymorphism prognostic significance and was analyzed by
the Kaplan–Meier method. The Log-rank test was used for the
comparison of different groups of patients. The difference was
considered as statistically significant at p < 0.05.
Results: A minor allele 238(A) was found in 10% BC patients
and in 7% women from control group. In the same way allele
308(A) was found with a close frequency in BC patients and con-
trols (25% and 22%). It worth to note that allele Awas found in two
position simultaneously in <1% of persons only. So, we failed to
reveal the association of both TNF polymorphisms with BC pre-
disposition. We did not reveal genotype distribution disparities
among groups with various stages of BC and the level of ER, PR
and Her2 expression. While highly active allele Val655 HER2 was
more frequent in BC patients with allele 238(A) then without
substitution (75% and 39%, accordingly, p < 0.05). We found that
10-year OS of BC patients was significantly lower in the presence
of allele 238(A) than without it in groups possessed regional
metastases (43 ± 13% and 72 ± 4%, p < 0.005) or ER + PR + tumor
(63 ± 17% and 89 ± 4%, p < 0.02). An opposite relationship was
obtained in the presence of allele 308(A) then without the
substitution when the tumor size was more than 5 cm (10-year
OS 69 ± 12% and 40 ± 8%, accordingly, p < 0.05).
Conclusions: This study found out the opposite effect of poly-
morphisms at 238 and 308 positions in TNF promoter on the
outcome of BC patients. Carriers of low expressed allele 238(A)
have poor outcome because of low response to standard hormone
therapy which presumably connected with the activation of Her2
pathway. The obtained results allow supposing that a special approach
to the treatment of this group of BC patients should be used.
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The origin of evolutionary novel genes is connected with the
origin and evolution of the novel organismal functions and the
increase in morphological complexity of multicellular organisms.
Novel gene acquire new or altered functions. Here we describe
that evolutionary novel genes, expressed predominantly in trans-
genic fish tumors after their induced regression, determine pro-
gressive evolutionary characters and are conserved in human.
We used a sample of genes, which were activated in inducible
krasV12 transgenic zebrafish tumors according to the results of
RNASeq data. Genes from our sample were expressed after HCC
regression upon kras inactivation. The search of orthologs by dif-
ferent tools, such as blastx and psiblast, with e-value cut off not
less than 10–3 and query coverage more than 50%, discovered that
considerable proportion of tumor-specifically expressed genes are
evolutionary novel, i.e. their orthologs are not found in Lamprey.
Nine tenths of these novel genes have orthologs in humans. Gene
ontology (GO) data were used to analyze their functions. Accord-
ing to the results of GO, some of the genes have functions not
characteristic to fish. Among known functions of the human
orthologues of evolutionary novel genes of zebrafish (vs. Lam-
prey) there are some important morphogenetic functions. For
example, genes ccdc40, lmx1ba and lepa acquired functions in
lung, embryonic utera and placenta, i.e. organs originated in taxa
higher than fish. A large proportion of genes from our sample are
connected with retina type eye, heart and brain development.
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